Shorts

Dr. Lowentritt's LUGPA 2027 pick: Friday afternoon breakouts

Correcting misconceptions about hormone therapy for GSM

How gravity instillation may improve gem/doce feasibility

Expert: Anktiva approval sets precedent for papillary-only NMIBC

Why underactive bladder stays under the radar

The hidden long-term cost of OAB step therapy

PCARE and PROs: Addressing penile cancer's hidden burden

Exploring intranasal PDE5 inhibitor delivery for erectile dysfunction

Challenging misconceptions about proximal shunting

Belzutifan plus lenvatinib offers a new option after IO in ccRCC

Decipher score may help guide short-term ADT use

Cost-effectiveness model favors beta-3 agonists for OAB

New treatment options complicate BCG-unresponsive NMIBC care

Why female sexual health is often overlooked in bladder cancer care

How APPs can expand access to clinical trials

What policymakers must do to preserve patient choice

Why the bladder diary matters in nocturia workup

3 actionable steps to improve PSMA-PET access

Site-neutral payment and the future of community urology

Reassessing goals of care throughout cancer treatment

Neoadjuvant therapy before prostatectomy: Assessing functional outcomes

How unequal PSMA-PET access may affect prostate cancer care

What a positive NeoBLAST trial would mean for MIBC care

Why independent urology practices face growing pressure

The long-term cost question behind OAB drug selection

How to spot patients chasing a product, not a diagnosis

How NeoBLAST defines and confirms complete response

Considering the practical benefits of intraoperative chemotherapy at nephroureterectomy

What the evidence says on penile cancer margin management

4 steps to implementing a rapid access model for elevated PSA